Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed.

 
Web www.patentalert.com

< Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid

< DNA molecule encoding a mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof

> DB, the receptor for leptin

> Method of grouping and analyzing clinical risks, and system therefor

~ 00278